Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.

Oratz R, Kim B, Chao C, Skrzypczak S, Ory C, Bugarini R, Broder M.

J Oncol Pract. 2011 Mar;7(2):94-9. doi: 10.1200/JOP.2010.000046.

2.
3.

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.

Levine MN, Julian JA, Bedard PL, Eisen A, Trudeau ME, Higgins B, Bordeleau L, Pritchard KI.

J Clin Oncol. 2016 Apr 1;34(10):1065-71. doi: 10.1200/JCO.2015.62.8503. Epub 2015 Nov 23.

PMID:
26598746
4.

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.

Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N.

J Natl Cancer Inst Monogr. 2001;(30):62-6.

PMID:
11773294
5.

Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer.

Yamauchi H, Nakagawa C, Takei H, Chao C, Yoshizawa C, Yagata H, Yoshida A, Hayashi N, Hell S, Nakamura S.

Clin Breast Cancer. 2014 Jun;14(3):191-7. doi: 10.1016/j.clbc.2013.10.017. Epub 2013 Oct 26.

7.

Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer.

Oratz R, Paul D, Cohn AL, Sedlacek SM.

J Oncol Pract. 2007 Jul;3(4):182-6. doi: 10.1200/JOP.0742001.

8.
9.

Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence.

Fisher BJ, Perera FE, Cooke AL, Opeitum A, Venkatesan V, Dar AR, Stitt L.

Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):541-50.

PMID:
9231678
10.

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.

Henry NL, Somerfield MR, Abramson VG, Allison KH, Anders CK, Chingos DT, Hurria A, Openshaw TH, Krop IE.

J Clin Oncol. 2016 Jul 1;34(19):2303-11. doi: 10.1200/JCO.2015.65.8609. Epub 2016 Mar 21.

PMID:
27001586
11.
12.

The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.

de Boer RH, Baker C, Speakman D, Chao CY, Yoshizawa C, Mann GB.

Med J Aust. 2013 Aug 5;199(3):205-8.

PMID:
23909545
13.

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.

Martín M, González-Rivera M, Morales S, de la Haba-Rodriguez J, González-Cortijo L, Manso L, Albanell J, González-Martín A, González S, Arcusa A, de la Cruz-Merino L, Rojo F, Vidal M, Galván P, Aguirre E, Morales C, Ferree S, Pompilio K, Casas M, Caballero R, Goicoechea U, Carrasco E, Michalopoulos S, Hornberger J, Prat A.

Curr Med Res Opin. 2015 Jun;31(6):1129-37. doi: 10.1185/03007995.2015.1037730. Epub 2015 Apr 23.

PMID:
25851308
14.

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S, Wolmark N.

J Clin Oncol. 2011 Nov 20;29(33):4365-72. doi: 10.1200/JCO.2011.35.3714. Epub 2011 Oct 17.

15.

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A.

Ann Oncol. 2012 Mar;23(3):625-31. doi: 10.1093/annonc/mdr278. Epub 2011 Jun 6.

PMID:
21652577
16.

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.

Geffen DB, Abu-Ghanem S, Sion-Vardy N, Braunstein R, Tokar M, Ariad S, Delgado B, Bayme M, Koretz M.

Ann Oncol. 2011 Nov;22(11):2381-6. doi: 10.1093/annonc/mdq769. Epub 2011 Mar 1.

PMID:
21363879
17.

The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.

Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, Daly MB, Goldstein LJ.

Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):669-77.

PMID:
8690632
18.

Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer.

Cartwright T, Chao C, Lee M, Lopatin M, Bentley T, Broder M, Chang E.

Curr Med Res Opin. 2014 Feb;30(2):321-8. doi: 10.1185/03007995.2013.855183. Epub 2013 Nov 7.

PMID:
24127781
19.

The influence of a gene expression profile on breast cancer decisions.

Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW.

J Surg Oncol. 2009 May 1;99(6):319-23. doi: 10.1002/jso.21244.

PMID:
19204954

Supplemental Content

Support Center